Stem Cell Signaling Measured for the 1st Time
2006年4月12日 - 10:00PM
PRニュース・ワイアー (英語)
Firefly(TM) 3000 Assay Platform Monitored the Phosphorylation Forms
of ERK PALO ALTO, Calif., April 12 /PRNewswire/ -- Researchers from
MIT, supported by Cell BioSciences' just released Firefly 3000
protein assay platform, measured ERK phosphorylation in scarce
hematopoietic stem cells from mice. Like many important cell
signaling kinases, ERK affects cells based on its phosphorylation
state. Activation of ERK through cell signaling pathways leads to
cellular responses including proliferation, differentiation and
survival. Since stem cells are always small in number, researchers
have precious few cells with which to experiment. The Firefly 3000
system allowed the MIT researchers to use minimal numbers of cells
and still obtain quantitative information. "The CellBio system let
us measure, for the first time, the effect of a hormone on
signaling in a minute number of purified stem cells," said Harvey
Lodish, Professor of Biology and Founding Member of the Whitehead
Institute of MIT. "The importance of this finding is that now the
Firefly 3000 gives us a reliable system for measuring the results
of treatments on various protein kinases involved in stem cell
growth and differentiation." Roger O'Neill, VP of Science &
Technology at CellBio added, "Many experiments have been limited by
protein measurement systems that require large samples and abundant
proteins. The Firefly 3000 allows researchers to measure the
activity of even low abundance proteins from precious samples such
as stem cells and fine needle biopsies. Our results show that the
Firefly 3000 can reliably measure various forms of proteins
responsible for cell signaling events and will be valuable in assay
development for biomarkers." Part of this research project was
supported by Serologicals Corporation who provided the antibodies
used for identification and detection of the ERK protein
phosphorylation forms. About Cell Biosciences Cell Biosciences is a
provider of life science instrumentation systems for protein
measurement and identification. The Company designs, manufactures,
markets and supports the nano-fluidics immunoassay platform called
the Firefly(TM) 3000, providing a powerful tool for scientific
investigation in biochemistry, hematology, immunology, and
oncology. The Firefly system automates and streamlines the tedious
technique of western blotting by eliminating the blotting step and
substantially reducing the number of handling steps. Cell
Biosciences is located in Palo Alto, CA and can be reached by phone
(650 859 1485); on its website (http://www.cellbiosciences.com/) or
by email (). About Serologicals Corporation Serologicals
Corporation (NASDAQ:SERO), headquartered in Atlanta, GA., is a
global leader in developing and commercializing consumable
biological products, enabling technologies and services in support
of biological research, drug discovery, and the bioprocessing of
life-enhancing products. Our customers include researchers at major
life science companies and leading research institutions involved
in key disciplines, such as neurology, oncology, hematology,
immunology, cardiology, proteomics, infectious diseases, cell
signaling and stem cell research. In addition, Serologicals is the
world's leading provider of monoclonal antibodies for the blood
typing industry. Serologicals employs a total of approximately
1,000 people worldwide in three Serologicals' companies: Chemicon
International headquartered in Temecula, California, Upstate Group,
LLC, headquartered in Charlottesville, Virginia and Celliance
Corporation, headquartered in Atlanta, Georgia. For more
information, please visit our website:
http://www.serologicals.com/. Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Such statements are made based on management's
current expectations and beliefs. Actual results may vary from
those currently anticipated based upon a number of factors
including the ability of Cell Bioscience's products to enhance
research or achieve market acceptance. The company undertakes no
obligation to release publicly any revision, which may be made to
reflect events or circumstances after the date hereof. DATASOURCE:
Cell BioSciences Inc. CONTACT: Howard D. Goldstein of Cell
BioSciences Inc., +1-650-859-1313, or Web site:
http://www.cellbiosciences.com/ http://www.serologicals.com/
Copyright
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 5 2024 まで 6 2024
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Serologicals (MM) (ナスダック市場): 0 recent articles
その他のSerologicals (MM)ニュース記事